Synapse - Works

Results (22468)

Phase Ib/II trial of the Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib, in combination with rituximab and lenalidomide in refractory/recurrent primary (PCNSL) and secondary central nervous system lymphoma (SCNSL)

Meeting Abstract

Grommes, C.; Piotrowski, A.; Pentsova, E.; Gavrilovic, I.; Stone, J. B.; Lin, A.; Wongchai, V.; Madzsar, J. T.; Malani, R.; Nolan, C.; more...
Blood (2022)

Fulltext@MSK | Save

Escape from type II JAK2 inhibition in MPN depends on AXL/MAPK activation and is targetable

Meeting Abstract

Codilupi, T.; Szybinski, J.; Brkic, S.; Stivala, S.; Yang, J.; Ghosh, N.; Buczak, K.; Passweg, J.; Angelillo-Scherrer, A.; Dirnhofer, S.; more...
Blood (2022)

Fulltext@MSK | Save

Emapalumab for malignancy-associated hemophagocytic lymphohistiocytosis: The Memorial Sloan Kettering Cancer Center experience

Meeting Abstract

Johnson, W. T.; Epstein-Peterson, Z. D.; Ganesan, N.; Chang, T.; Galasso, N.; Stuver, R.; Khan, N.; Salles, G.; Moskowitz, A. J.; Vardhana, S.; more...
Blood (2022)

Fulltext@MSK | Save

Long-term outcome of patients with follicular lymphoma is not fundamentally affected by KMT2D, EZH2, and CREBBP mutational status

Meeting Abstract

Bantilan, K. S.; Rutherford, K.; McCarter, J.; Farnoud, N.; Arango-Ossa, J. E.; Papaemmanuil, E.; Zelenetz, A. D.
Blood (2022)

Fulltext@MSK | Save

Fructose treatment targets myeloid leukemogenesis in IDH2 mutants by exhausting alpha-ketoglutarate pools

Meeting Abstract

Savino, A. M.; Turner, B.; Jeong, S.; Schild, T.; Yang, X.; Luo, H.; Chirayil, R.; Cullen, Q.; Chan, M.; Han, G.; more...
Blood (2022)

Fulltext@MSK | Save

NX-2127-001, first-in-human trial of NX-2127, a Bruton's tyrosine kinase-targeted protein degrader, in patients with relapsed or refractory chronic lymphocytic leukemia and B-cell malignancies

Meeting Abstract

Mato, A. R.; Wierda, W. G.; Ai, W. Z.; Flinn, I. W.; Tees, M.; Patel, M. R.; Patel, K.; O'Brien, S.; Bond, D. A.; Roeker, L. E.; more...
Blood (2022)

Fulltext@MSK | Save

Systematic evaluation of AML-associated antigens identifies novel anti-U5 snRNP200 therapeutic antibodies for the treatment of AML

Meeting Abstract

Knorr, K.; Erickson, C.; Wang, E.; Rahman, J.; Mi, X.; Lu, S.; Fox, N.; Penson, A.; Hogg, S.; Stanley, R.; more...
Blood (2022)

Fulltext@MSK | Save

Single cell genotypic and phenotypic analysis of measurable residual disease in acute myeloid leukemia

Meeting Abstract

Robinson, T.; Bowman, R. L.; Persaud, S.; Liu, Y.; Gao, Q.; Zhang, J. P.; Sun, X.; Sciambi, A.; Llanso, A.; Famulare, C.; more...
Blood (2022)

Fulltext@MSK | Save

Tracking the evolution of therapy-related myeloid neoplasms using chemotherapy signatures

Meeting Abstract

Ziccheddu, B.; Diamond, B.; Maclachlan, K. H.; Taylor, J.; Boyle, E. M.; Arango Ossa, J. E.; Jacob, J.; Affer, M.; Totiger, T. M.; Coffey, D.; more...
Blood (2022)

Fulltext@MSK | Save

Patient-derived iPSCs faithfully represent the genetic diversity and cellular architecture of human acute myeloid leukemia

Meeting Abstract

Cruz-Rodriguez, N.; Kotini, A. G.; Carcamo, S.; Olszewska, M.; Bernard, E.; Luo, H.; Kharas, M. G.; Hasson, D.; Papapetrou, E. P.
Blood (2022)

Fulltext@MSK | Save